{"id":"W4407576339","doi":"10.1038/s41467-025-56619-x","title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute; Y-mAbs Therapeutics","keywords":"Medicine; Refractory (planetary science); Clinical endpoint; Internal medicine; Phases of clinical research; Population; Neuroblastoma; Gastroenterology; Bone pain; Interim analysis; Bone marrow; Adverse effect; Minimal residual disease; Progressive disease; Surgery; Clinical trial; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0009382461,0.0002740196,0.0005421212,0.0002098721,0.001356716,0.0001053576,0.001257704,0.000457875,0.00001761469],"category_scores_gemma":[0.006610659,0.0001738169,0.0004152964,0.000659089,0.0005402141,0.0001294084,0.0004982984,0.00287124,0.00003838625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001601659,"about_ca_system_score_gemma":0.001259736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003730676,"about_ca_topic_score_gemma":0.0003207567,"domain_scores_codex":[0.9970446,0.0007983265,0.0007905852,0.0004831158,0.0004016233,0.0004816998],"domain_scores_gemma":[0.9885961,0.007101236,0.0002909645,0.003258586,0.0005072423,0.000245855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4997156,0.02922077,0.004799114,0.0002188409,0.004665573,0.0002926867,0.0002134825,0.000008696167,0.007433317,0.02463806,0.2806601,0.1481338],"study_design_scores_gemma":[0.3144208,0.0116739,0.03317045,0.0002262763,0.001128622,0.00005579515,0.0001147229,0.003366447,0.0008062757,0.0008976692,0.6337742,0.0003648719],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9573974,0.004442793,0.0004127452,0.02754189,0.001835633,0.005726288,0.0004337044,0.0003027168,0.001906843],"genre_scores_gemma":[0.9853654,0.00576891,0.003893187,0.0009198528,0.0002534367,0.0004678391,0.0004572491,0.00004589453,0.00282827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3531142,"threshold_uncertainty_score":0.9999434,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06358709569426185,"score_gpt":0.4778914031717435,"score_spread":0.4143043074774816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}